Agios Pharmaceuticals, Inc.

Good morning, and welcome to AGIOS's fourth quarter 2021 conference call. At this time, all participants are in listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at AGIOS's request. I would now like to turn the call over to Holly Manning, Senior Director of Investor Relations.

Thank you, Operator. Good morning, everyone, and welcome to AGIOS's fourth quarter 2021 conference call. You can access slides for today's call by going to the Investor section of our website, agios.com. With me on the call today with prepared remarks are Dr. Jackie Faust, our Chief Executive Officer, Dr. Sarah Guins, our Chief Medical Officer, Richa Poddar, our Chief Commercial Officer, Jonathan Biller, our Chief Financial Officer and Head of Corporate Affairs, and Dr. Bruce Carr, our Chief Scientific Officer, who will join for Q&A. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. With that, I will turn the call over to Jackie.

Thank you, Holly. Good morning, everyone, and thanks for joining our fourth quarter 2021 results call. As I reflect on 2021, I'm reminded of this time last year when we had just recently announced our decision to divest our oncology business and were in the thick of creating a plan for the next chapter of Augeos focused solely on genetically defined diseases. Today, 12 months later, I'm astounded at what we've been able to accomplish together with our teams across all areas of the business. and I'm incredibly optimistic about the future that we are building toward. On the heels of our FDA approval of Pyrocon last week, our commercial team is off to the races, engaging with physicians and educating on PK deficiency. Richa, who joins us for her first earnings call in her new role as Chief Commercial Officer, will provide more insight into our commercial launch strategy. Our clinical team is moving full speed ahead, enrolling our thalassemia and sickle cell disease pivotal studies, while also working through startup activities for our pediatric PK deficiency pivotal trials, the AG946 phase one sickle cell disease cohort, and the AG946 MDS study. As always, our research organization continues to focus on the next wave of discovery and preclinical programs, which we laid out at our investor day back in November. Importantly, because our oncology business divestiture provided us with significant cash and a strong balance sheet that supports our near and long-term business strategy, we can remain focused on executing against our business priorities during a time when financial markets are volatile and uncertain. Last year, we reduced our share count by more than 23 percent through our share repurchase program while retaining financial flexibility to accelerate programs in our pipeline and potentially pursue complementary business development opportunities that could arise. As we look ahead to this year, we're committed to continuing our track record of strong execution across research, clinical, and commercial. With that, I'll turn it over to Sarah.